News
Foghorn CEO bets on selectivity for undisclosed IBD drug and EP300 degrader after dropping FHD-909, at Jefferies London
Foghorn Therapeutics chief executive Adrian Gottschalk told the Jefferies Global Healthcare Conference in London that an undisclosed oral IBD drug and a selective EP300 degrader lead the company's mostly preclinical pipeline after FHD-909 was not advanced.



